Vertaling van "case the intent-to-treat analysis " (Nederlands → Frans) :

In this case the intent-to-treat analysis can give unrealistically narrow confidence intervals if substantial numbers of patients elect to have the treatment they were not randomized to receive 21 .
In this case the intent-to-treat analysis can give unrealistically narrow confidence intervals if substantial numbers of patients elect to have the treatment they were not randomized to receive 22 .

Het gemiddelde uitgangswaardeniveau voor CD4 celgetal was 337 cellen/mm 3 (variërend van 14 tot 1,543 cellen/mm 3 ) en het gemiddelde uitgangsniveau voor de plasma hiv-1 RNA spiegel was 4,4 log 10 kopieën/ml (variërend van 2,6 tot 5,88 log 10 kopieën/ml). b ATV/RTV met tenofovir/emtricitabine (vaste dosis 300 mg/200 mg tabletten eenmaal daags). c LPV/RTV met tenofovir/emtricitabine (vaste dosis 300 mg/200 mg tabletten eenmaal daags). d betrouwbaarheidsinterval e Aantal evalueerbare patiënten. f Intent-to-treat analysis, met ontbrekende waarden beschouwd als “falers”. Responders op LPV/RTV die hun behandeling
Les valeurs initiales moyennes des taux de CD4 étaient 337 cellules/mm 3 (intervalle : 14 à 1 543 cellules/mm 3 ) et les valeurs initiales des taux d’ARN-VIH étaient de 4,4 log 10 copies/ml (intervalle : 2,6 à 5,88 log 10 copies/ml) b ATV/RTV associé à ténofovir/emtricitabine (dose fixe de 300 mg/200 mg en comprimés une fois par jour). c LPV/RTV associé à ténofovir/emtricitabine (dose fixe de 300 mg/200 mg en comprimés une fois par jour).

Table 8: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)
Table 10: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)

scope and purpose: 10/12 stakeholders involvement: 8/16 rigour of development: 7/28 (methods available only on request) clarity and presentation: 8/16 applicability: 3/12 editorial independence: 2/8 question: adequate search: insufficient selection: unclear quality appraisal: fair data-extraction: not given characteristics of original studies: not given meta-analysis: no pooling Randomisation: good concealment of allocation: no Blinding of outcome assessors: unclear Baseline characteristics comparable: yes Follow-up: sufficient Intention-to-treat: yes Contamination: unclear
scope and purpose: 10/12 stakeholders involvement: 8/16 rigour of development: 7/28 (methods available only on request) clarity and presentation: 8/16 applicability: 3/12 editorial independence: 2/8 question: adequate search: insufficient selection: unclear quality appraisal: fair data-extraction: not given characteristics of original studies: not given meta-analysis: no pooling